Navigation Links
Endologix to Acquire Nellix
Date:10/27/2010

IRVINE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has signed a definitive agreement to acquire Nellix, Inc, a privately-held medical device company that has developed a revolutionary endograft for the treatment of Abdominal Aortic Aneurysms (AAAs).

Under the terms of the agreement, Endologix will acquire Nellix for $15 million in stock at closing, plus additional milestone-based, stock payments of up to $39 million. The agreement also includes a commitment for a $15 million equity investment in Endologix from Essex Woodlands Health Ventures, the majority shareholder of Nellix. Endologix anticipates that the closing of the transactions will occur in the fourth quarter of 2010, subject to approval of the stockholders of Endologix and certain other customary closing conditions.  The shares of Endologix's common stock to be issued to stockholders of Nellix and to Essex Woodlands will not be registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Nellix has developed a highly differentiated technology platform that completely seals and fills an aortic aneurysm sac, preventing device migration and potentially improving clinical outcomes. This allows the product to treat a wide range of AAA anatomies, including those that are outside of the indications for existing Endovascular Aortic Repair (EVAR) devices. These include patients with aortic neck lengths of 5 millimeters or less, widths as wide as 34 millimeters, and patients with iliac aneurysm diameters greater than 23 millimeters. Initial clinical results from patients with up to two years follow-up have shown 100% implant success; 100% freedom from AAA-related mortali
'/>"/>

SOURCE Endologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Endologix Reports 30% Third Quarter 2010 Revenue Growth
2. Endologix to Present at Oppenheimer 21st Annual Healthcare Conference
3. Endologix Announces Publication of Clinical Trial Results Supporting Anatomical Fixation with a Suprarenal Aortic Extension
4. Endologix to Report Third Quarter 2010 Financial Results on October 27, 2010
5. Endologix Receives CE Mark Approval for Expanded Line of Powerlink Products and PowerFit Aortic Extensions
6. Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology
7. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
8. Endologix Reports 47% Third Quarter 2009 Revenue Growth
9. Endologix to Report Third Quarter 2009 Financial Results on October 27, 2009
10. Endologix Responds to Alleged Patent Infringement
11. Endologix Comments on Alleged Patent Infringement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... , July 30, 2015 Takeda Pharmaceutical ... study to fulfill the post-marketing commitment and submissions ... Pan European Multi-Database Bladder Cancer Risk Characterization Study ... cohort study, conducted in four European countries, for ... up to 10 years of follow-up. Findings demonstrate ...
(Date:7/30/2015)... , July 30, 2015  Big Cloud Analytics, ... analytics technology, announces it is working with Intel ... for the new Lockheed Martin Healthcare Technology Alliance. ... health information technology providers, medical technology companies and ... and innovation to improve care in rapidly evolving ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3
... ... Reportlinker.com announces that a new market research report ... Markets for Breast Biopsy Devices 2009 , ... markets for breast biopsy devices includes the spring ...
... , NATICK, Mass. and LONDON, Nov. ... ) today announced that it has received 510(k) clearance ... CE Mark approval to market its WallFlex® Fully Covered ... (obstructions) caused by tumors in patients with resectable or ...
Cached Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... As ... programs, the activity of recruiting patients becomes a serious challenge. Because of growing competition, ... program to patients within the local community. , The team at Wound ...
(Date:7/30/2015)... Angeles, CA (PRWEB) , ... July 30, 2015 , ... The connection between a healthy ... and women. The loss of a full head of hair can have a devastating ... how a person is perceived in the work place, the consequences of hair loss are ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is proud to ... San Diego, California’s Gaslamp Quarter Plaza for five years this September. , The ... the area for any suspicious activity. These cameras are in place to provide ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... into one of the largest, family-owned low cost service and repair companies. For ... applications, as well as growing their company to meet the demands of the ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... “Beachside Nursing Center,” to announce its position as one of Medicare’s top-rated ... and staff members support the CMS rating system, which monitors health inspections, ...
Breaking Medicine News(10 mins):Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 2Health News:Bill Howe Plumbing, Heating & Air Launches Online Application to Prospective Employees 3Health News:Beachside Nursing Center Releases New Video 2
... diseases, bringing in hope where ... there is none!, ... resigned to a life of pain with Rheumatoid Arthritis is healthy,and normal ... my,Good Shepherd, Jesus and His own good shepherd, Dr. Omar, have rescued ...
... DCGN ) today announced that it will host ... the Lazard Capital Markets 4th Annual,Healthcare Conference., The ... Tuesday, November,27 at the Palace Hotel, New York City. ... deCODE,s website, http://www.decode.com, and those,interested in listening ...
... Contaminated water could boost child,s cancer risk, study finds ... women exposed to arsenic-contaminated water during pregnancy have gene ... diseases later in life, a Massachusetts Institute of Technology ... work is the first documentation of widespread genetic ...
... AIDS Treatment Provision on World AIDS ... ... to an,increasing need for more effective AIDS treatments in India and recent,high-profile ... Organization (NACO) and Health Minister A.,Ramadoss will announce the rollout of lifesaving ...
... individual has on receiving his paycheque depend critically on ... comes from an experiment conducted by economists and brain ... subjects in pairs, asking them to perform a simple ... tomographs, the researchers examined the volunteers, brain activity throughout ...
... also encourages midday sleepiness, experts say, , , THURSDAY, Nov. ... heads after the Thanksgiving feast aren,t rare, and experts ... during the holiday. , It may have to do ... in tryptophan -- a chemical known to promote sleepiness, ...
Cached Medicine News:Health News:Stem Cells- Dr. Omar Gonzalez' Therapy for all Ills! 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 2Health News:NACO Bows to Activists' Pressure on AIDS Treatment in India, Says AHF 3Health News:Money motivates -- especially when your colleague gets less 2Health News:Money motivates -- especially when your colleague gets less 3Health News:There's More Than Turkey Behind Holiday Yawns 2
... No need to add individual components ... range of trauma indications. Made of an ... than conventional fixators, only much lighter. This ... apply, and more comfortable for the patient. ...
... an X-ray contrast medium for ... for: angiography, urography, phlebography and ... of the basal cisterns, following ... cholangio (pancreato) graphy (ERC(P)), herniography, ...
... (gadobenate dimeglumine) is a paramagnetic MRI contrast ... with gadobenate, a chelating agent that forms ... godolinium ion. It is salified with meglumine ... with all the physico-chemical features typical of ...
... ferumoxides) is Advanced Magnetics' contrast agent for use ... It is the first organ-specific MRI contrast agent ... function, the agent is taken up by macrophages ... in most tumors. The liver is a principal ...
Medicine Products: